Cardiovascular safety risks associated with gout treatments
Giovanna Rosas1, Angelo Gaffo1, Elizabeth J Rahn1
1Department of Medicine, University of Alabama at Birmingham , Birmingham, AL, USA.
Expert Opinion on Drug Safety
|August 1, 2020
Summary
Gout medications can reduce cardiovascular risks. Allopurinol demonstrates cardiovascular safety compared to other urate-lowering therapies, while colchicine and IL-1 inhibitors show promising results needing further research.
Area of Science:
- Rheumatology
- Cardiology
- Pharmacology
Background:
- Uric acid, a purine metabolism byproduct, accumulates due to reduced excretion, potentially damaging organ systems like the cardiovascular system.
- Elevated uric acid levels are increasingly linked to cardiovascular disease and impact the safety profile of gout medications.
- Cardiovascular disease burden necessitates understanding the relationship between urate levels, cardiovascular outcomes, and gout treatment safety.
Purpose of the Study:
- To review common gout therapies for serum urate reduction and flare management.
- To analyze the cardiovascular effects of these gout medications based on clinical trials and observational studies.
- To present recommendations from major Rheumatology guidelines regarding gout management and cardiovascular safety.
Main Methods:
- Selection of representative clinical studies evaluating cardiovascular outcomes for each gout therapy.
- Review of recommendations from prominent Rheumatology society guidelines.
- Analysis of observational and clinical trial data on gout therapies and cardiovascular disease.
Main Results:
- Gout treatment can decrease joint damage and reduce cardiovascular morbidity.
- Allopurinol exhibits a favorable cardiovascular safety profile compared to other urate-lowering therapies (ULTs).
- Colchicine and Interleukin-1 (IL-1) inhibitors show promising evidence for cardiovascular safety, warranting further investigation.
Conclusions:
- Therapeutic interventions for gout can mitigate both joint damage and cardiovascular risks.
- Allopurinol is identified as a ULT with a demonstrated cardiovascular safety profile.
- Further research is recommended to confirm the cardiovascular safety of colchicine and IL-1 agents in gout management.
Related Concept Videos
01:20Exercise and Cardiovascular Response
3.7K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
3.7K
01:24Chronic Kidney Disease II: Clinical Manifestations
427
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
427
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
771
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
771
01:27Peripheral Artery Disease III: Interprofessional Care
161
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
161
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.8K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
928
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
928